Guhwe Mary, Utley-Smith Queen, Blessing Robert, Goldstein Larry B
Department of Neurology, Duke University Medical Center, Durham, NC, United States.
Duke University School of Nursing, Durham, NC, United States.
J Stroke Cerebrovasc Dis. 2016 Mar;25(3):540-2. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.006. Epub 2015 Dec 8.
Obtaining a routine computed tomography (CT) brain scan 24 hours after treatment with intravenous tissue plasminogen activator (IV-tPA) is included in the American Heart Association/American Stroke Association acute stroke guidelines. The usefulness of the test in stable patients is not known. We hypothesized that the results of routine, 24-hour post-treatment neuroimaging (CT or magnetic resonance imaging [MRI] brain scans) would not alter the management of clinically stable patients.
Patients treated with IV-tPA between January 2011 and December 2013 were identified from a single hospital's stroke registry. All patients were closely monitored for changes in stroke severity. Demographics, changes in neurological status, neuroimaging results, and changes in therapy were abstracted from the patients' medical records. Patients having a neuroimaging study because of neurological deterioration were excluded.
Of 136 patients treated with IV-tPA, 131 met criteria for inclusion. Of these, 86.7% had moderate to severe neurological deficits (i.e., initial National Institutes of Health Stroke Scale score > 5 points; median 8 points). All patients had routine imaging ~24 hours after treatment (CT brain 62.6%, MRI brain 12.4%, both CT and MRI brain 25%). Asymptomatic hemorrhagic transformation occurred in 6.7% and potentially changed management in a single patient (target systolic blood pressure was lowered from 185 to 180 mmHg).
Over a 3-year period, routine neuroimaging ~24-hours after IV-tPA in clinically stable patients was associated with a change in therapy in only 1 (.95%) patient. If confirmed in other cohorts, these results suggest that routine neuroimaging after IV-tPA may be safely avoided in clinically stable patients, eliminating unnecessary radiation exposure in those having CT brain and reducing costs.
美国心脏协会/美国卒中协会急性卒中指南中包括在静脉注射组织纤溶酶原激活剂(IV-tPA)治疗24小时后进行常规脑部计算机断层扫描(CT)。该检查在病情稳定患者中的作用尚不清楚。我们推测,常规的治疗后24小时神经影像学检查(CT或磁共振成像[MRI]脑部扫描)结果不会改变临床稳定患者的治疗管理。
从一家医院的卒中登记处识别出2011年1月至2013年12月期间接受IV-tPA治疗的患者。所有患者均密切监测卒中严重程度的变化。从患者的病历中提取人口统计学信息、神经功能状态变化、神经影像学结果和治疗变化。因神经功能恶化而进行神经影像学检查的患者被排除。
在136例接受IV-tPA治疗的患者中,131例符合纳入标准。其中,86.7%有中度至重度神经功能缺损(即初始美国国立卫生研究院卒中量表评分>5分;中位数8分)。所有患者在治疗后约24小时进行了常规成像检查(脑部CT检查占62.6%,脑部MRI检查占12.4%,脑部CT和MRI检查均做的占25%)。无症状性出血转化发生率为6.7%,仅1例患者的治疗可能因此改变(目标收缩压从185 mmHg降至180 mmHg)。
在3年期间,临床稳定患者在IV-tPA治疗后约24小时进行的常规神经影像学检查仅使1例(0.95%)患者的治疗发生改变。如果在其他队列中得到证实,这些结果表明,临床稳定患者可安全避免在IV-tPA治疗后进行常规神经影像学检查,从而消除脑部CT检查患者的不必要辐射暴露并降低成本。